Jul 27,2023

IMAGIO Consortium Receives Innovative Health Initiative EUR 24 Million Grant to Improve Cancer Treatments

Royal Philips announced that the Philips-coordinated IMAGIO consortium of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners, to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 27,2023

PathAI Launches its AI-Powered PathExplore Data Access Program For Academic Researchers

PathAI, a global leader in AI-powered pathology, today announced it has applied its PathExplore panel of human interpretable features (HIFs) on publicly available samples from The Cancer Genome Atlas (TCGA), a comprehensive resource of oncology data containing genomic and outcomes data, along with associated H&E whole-slide images (WSIs). PathAI will make the HIFs from eight TCGA cancer types available for free as a data access program for academic researchers to perform independent research to support their own investigations. Powered by artificial intelligence, PathExplore spatially characterizes the TME with single-cell resolution, giving researchers the ability to unlock insights on patient response, drug pathways, and potential novel biomarkers.

PRODUCT

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 20,2023

PathAI Launches AIM-HER2 Breast Cancer, an Artificial Intelligence-Powered HER2 Scoring Algorithm for Biopharma Research and Clinical Labs

PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced the availability of AIM-HER2 Breast Cancer[i] for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to visualize the slide features driving the algorithm’s predicted score. AIM-HER2 will be available to biopharma researchers and clinical research lab pathologists on PathAI’s AISight digital pathology platform in both the clinical research lab and clinical trial setting.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 18,2023

Massive Bio and CureMatch Announce Groundbreaking Partnership to Revolutionize Cancer Treatment through AI and Clinical Trial Accessibility

Massive Bio and CureMatch, a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, have joined forces in a transformative partnership aimed at revolutionizing cancer treatment. In this game-changing alliance, CureMatch will harness its distinctive platform to identify patients who stand to benefit most from groundbreaking clinical trials, thereby magnifying the reach and impact of Massive Bio's trials. Simultaneously, Massive Bio will employ its cutting-edge AI capabilities to process a wealth of patient clinical health data, including variables such as cancer type, demographics, geographic location, and historical data.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jul 21,2023

Breast cancer diagnostic tool could save NHS £287m

The health economic study, carried out by Health Tech Connect and commissioned and funded by the UK government, concluded that the AI-powered tool would present huge savings in healthcare with much lower acquisition costs, transportation fees and a reduced prescription of chemotherapy, by as much as 30%. If the tool was utilised for other areas of cancer across the NHS it would offer even greater savings. Digistain has been inducted into the NHS Innovation Accelerator programme - mandated to help innovations spread throughout the NHS quickly. Clinical data unveiled at the American Society of Clinical Oncology in Chicago last month showed that Digistain demonstrated similar diagnostic accuracy to the current National Institute for Health and Care Excellence-approved cancer test. “The results indicate that Digistain can lead to statistically significant cumulative savings of an average of £286.7 million for an intermediate-risk patient population once rolled out as a substitute.”

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 18,2023

An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma

The EMulate Therapeutics Voyager™ is a simple, wearable, home-use device that uses an alternating electromagnetic field to alter biologic signaling within cells. The objective of this study is to assess the safety/feasibility of the Voyager in the treatment of recurrent glioblastoma (rGBM). In this study, patients with rGBM were treated with Voyager as monotherapy or in combination with standard chemotherapy at the Investigator's discretion. Safety was assessed by incidence of adverse events associated with the Voyager. A total of 75 patients were enrolled and treated for at least one day with the Voyager (safety population). Device-related adverse events were uncommon and generally did not result in interruption or withdrawal from treatment. The data support the safety and feasibility of the Voyager for the treatment of rGBM. Further prospective study of the device is warranted.

CLINICAL STUDY

#connected device

#dtx

View Analyst & Ambassador Comments
Go to original news
Jul 20,2023 TOP STORY

AppliedVR and National Cancer Institute Collaborate on Research Evaluating Virtual Reality for Reducing Anxiety in Primary Brain Tumor Patients During Imaging Services

AppliedVR, in collaboration with the National Cancer Institute (NCI), conducted a phase 2 clinical trial using virtual reality (VR) as an intervention for primary brain tumor patients, showing high feasibility and acceptability. VR therapy was found to positively impact patients' distress and anxiety levels.

COLLABORATION PARTNERSHIP

#r&d

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Jul 17,2023

LloydsPharmacy Clinical Homecare rolls out Careology with centralised triage system to support oncology patients

LloydsPharmacy Clinical Homecare adopts Careology's digital cancer care platform to enhance support for oncology patients. Nurses will use the system to triage patients, providing timely assessments and support, reducing hospital visits, and offering 24/7 direct access to the Oncology Nurse Specialist Team. Nurses working for LPCH, one of the leading providers in clinical homecare, will be the first to use Careology as part of a centralised system to triage patients, enabling nurses to promptly assess individuals and ascertain their specific requirements for enhanced support or urgent medical attention.

COLLABORATION PARTNERSHIP

#institution

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 19,2023

HealthPartners expands member access to digital cancer care

One year after piloting a new digital health service to support members undergoing cancer treatment, HealthPartners today announced that it is expanding the service to include 240,000 fully insured commercial members. Iris, developed by OncoHealth, enables members to connect with a team of cancer clinicians, nurses, social workers and peers any time of day via chat, phone, or video to discuss their cancer questions, including symptom and side-effect management, depression, anxiety, nutrition, sexual wellness and other aspects of treatment. During the initial pilot phase, 43% engaged with a member of the Iris clinical team, including nurses and mental health experts, with an average of 2.3 interactions a month, while 68% utilized a personalized, self-directed curriculum.

COLLABORATION PARTNERSHIP

#institution

#telehealth

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 13,2023 TOP STORY

Jasper Health and MSK Direct Launch Digital Solution to Bring Comprehensive Cancer Care Support to Employees Everywhere

Jasper Health, a leading digital oncology platform, in partnership with Memorial Sloan Kettering Cancer Center (MSK), today announced its launch of the MSK Direct digital platform. By combining MSK’s clinical subspecialized expertise with Jasper Health’s data-driven technology and human-led coaching support, the new MSK Direct app delivers cancer navigation and support to employees and their loved ones. The enhanced solution allows members to take control of their treatment plan throughout their cancer journey and enables broad access to support coaching, virtual expert medical opinions, and care navigation.

COLLABORATION PARTNERSHIP

#institution

#coaching

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY